Core Insights - Autonomix Medical, Inc. is expanding its clinical trials to include additional visceral cancer indications, effectively doubling its potential addressable market beyond pancreatic cancer pain [1][2] - The initiation of the PoC 2 phase follows positive results from the PoC 1 trial, which focused on patients with severe pancreatic cancer pain, indicating a strong foundation for multi-indication growth [2][3] - The company's technology platform has the potential to address a wide range of medical conditions, including cardiology, hypertension, and chronic pain management, with a concentrated focus on interventional cancer pain management applications [3][5] Company Overview - Autonomix Medical, Inc. is dedicated to advancing innovative technologies for diagnosing and treating diseases related to the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4][5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Insights - Autonomix Medical, Inc. has received Ethics Committee authorization to expand its clinical trials for a proprietary ablation technology aimed at treating visceral cancer pain, building on initial success in pancreatic cancer pain [2][3] - The follow-on phase of the clinical program (PoC 2) is set to begin patient enrollment in June 2025, with the potential to double the addressable market by including additional visceral cancers [2][3][4] Group 1: Clinical Development - The PoC 2 phase will evaluate the safety and effectiveness of delivering transvascular energy to ablate problematic nerves, with a focus on interventional cancer pain management applications [2][4] - Initial trials in late-stage pancreatic cancer patients showed promising results, including significant pain reduction and decreased opioid use, indicating the technology's potential to transform cancer pain management [3][4] Group 2: Market Expansion - The expansion into visceral cancer pain aligns with Autonomix's strategy to create long-term value through multi-indication growth, addressing significant unmet needs in cancer treatment [3][4] - The technology platform has the potential to address various indications beyond cancer, including cardiology and chronic pain management, indicating a broad market opportunity [4][6][7] Group 3: Technology Overview - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [6][7] - The investigational nature of the technology means it has not yet been cleared for marketing in the United States, highlighting its developmental stage [7]

Discussion in Virtual Investor CEO Connect focuses on Company’s planned follow-on market expansion study phase (“PoC 2”) of proof-of-concept trial; Access Here Additional indications potentially double the addressable market beyond pancreatic cancer pain Follow-on expansion phase expected to begin in Q2 2025 THE WOODLANDS, TX, May 13, 2025 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to rev ...